MediFind
LoginSign Up
Are we missing a condition or feature you’d like to see? MediFind is always evolving and we’d love your feedback.
MediFind
Condition

Urothelial Cancer

Symptoms, Doctors, Treatments, Research & More

Active Clinical Trials

Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 38
  • Start Date: December 31, 2020
A Phase II Trial of Pembrolizumab as Standard of Care + sEphB4-HSA in Chemotherapy Ineligible or Chemotherapy Refusing Patients With Metastatic Urothelial Carcinoma
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 80
  • Start Date: August 20, 2020
DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 26
  • Start Date: July 29, 2020
A Phase II Trial for the Use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG naïve Non-muscle Invasive Urothelial Carcinoma of the Bladder
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 20
  • Start Date: July 28, 2020
Tolerability and Activity of Neoadjuvant Infigratinib, an Inhibitor of FGFR, in Upper Tract Urothelial Carcinoma
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 66
  • Start Date: July 13, 2020
A Phase I Study of Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Clinical Trial
Biological
  • Status: Recruiting
  • Study Type: Biological
  • Participants: 260
  • Start Date: July 10, 2020
A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Clinical Trial
Procedure
  • Status: Recruiting
  • Study Type: Procedure
  • Participants: 12
  • Start Date: July 2020
Investigating Marrow Infiltrating Lymphocytes as a Source of Adoptive Cellular Therapy in Renal Cell Carcinoma and Urothelial Carcinoma
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 42
  • Start Date: May 21, 2020
A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)
Clinical Trial
Other
  • Status: Recruiting
  • Participants: 400
  • Start Date: May 18, 2020
An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation of Initial Treatment Pattern and Overall Survival in the Chinese Muscle Invasive Urothelial Bladder Carcinoma Patients
Clinical Trial
Biological
  • Status: Recruiting
  • Study Type: Biological
  • Participants: 183
  • Start Date: April 23, 2020
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 20
  • Start Date: March 23, 2020
A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 218
  • Start Date: March 11, 2020
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Showing 1–12 of 212 Clinical Trials
Next